Abivax Shares Plunge 32% Despite Positive Colitis Trial Results Amid Safety Concerns 

French biotech company Abivax delivered some of the strongest ulcerative colitis trial results seen in recent years. Yet, Abivax Shares (ABVX) plunged more than 32% on June 2, 2026, as investors focused on safety concerns rather than efficacy data. The selloff came after the company released positive Phase 3 maintenance trial results for its lead drug candidate, obefazimod, in patients with moderate-to-severe ulcerative colitis.

Strong Efficacy Fails to Ease Investor Concerns

The market reaction surprised many analysts. Clinical remission rates exceeded expectations, and the study met both primary and secondary endpoints. However, several malignancy cases reported during the trial overshadowed the strong efficacy profile. While investigators determined these cancer cases were unrelated to treatment, uncertainty around long-term safety weighed heavily on sentiment. As a result, Abivax’s valuation dropped sharply despite a major clinical milestone.

Biotech stocks often react strongly to safety-related headlines. Recent examples include companies such as Moderna, Sarepta Therapeutics, and BioNTech, where regulatory or safety developments significantly influenced share prices.

Abivax Shares Fall Despite Strong Phase 3 Results

Obefazimod Delivered Impressive Remission Rates

The Phase 3 ABTECT maintenance study enrolled 580 participants who had responded to earlier induction treatment. After 44 weeks, patients receiving 25 mg and 50 mg daily doses achieved clinical remission rates of 50.8% and 51.3%, respectively. The placebo group recorded a remission rate of only 10.4%.

Analysts highlighted the placebo-adjusted remission rates of 39.3% and 40.3%, calling them among the strongest ever reported in a large ulcerative colitis maintenance study. The drug also met all major secondary endpoints, including endoscopic improvement and corticosteroid-free remission.

Key Trial Metrics

Metric	Placebo	Obefazimod 25 mg	Obefazimod 50 mg
Clinical Remission	10.4%	50.8%	51.3%
Endoscopic Improvement	12.5%	N/A	64.1%
Endoscopic Remission	9.9%	N/A	47.7%
Trial Duration	44 Weeks	44 Weeks	44 Weeks
Participants	580 Total	580 Total	580 Total

Source: Abivax Phase 3 ABTECT Maintenance Trial Results.

Safety Concerns Trigger Market Selloff

Although efficacy exceeded expectations, investors focused on several malignancy cases reported in the higher-dose treatment group. During the study, researchers recorded cases of prostate cancer, breast cancer, and colon cancer. Each event represented approximately 0.5% of patients in the 50 mg group. Investigators concluded that the cases were unrelated to obefazimod treatment.

Additional skin cancer cases were also reported. While no clear pattern emerged and no organ-specific clustering was observed, the disclosures created uncertainty around future regulatory review and product labeling. That uncertainty drove a sharp decline in Abivax Shares despite the positive clinical outcome.

Important Safety Data

• No deaths were reported during the trial.
• Serious infections occurred in less than 1% of participants.
• Serious adverse events ranged between 2.6% and 5.6%.
• Treatment discontinuation rates remained below 7%.
• Investigators found no direct causal relationship between obefazimod and reported cancers.

What’s Next for Abivax? FDA Filing Planned for Late 2026

Despite the market reaction, Abivax remains on track to submit a New Drug Application to the U.S. Food and Drug Administration during the fourth quarter of 2026. The company is also advancing obefazimod into Crohn’s disease studies, with Phase 2b results expected in 2027.

Management continues to emphasize the drug’s differentiated profile. Analysts from Stifel and Leerink described the efficacy results as better than expected, though they acknowledged that safety questions could remain an overhang until regulators complete their review.

For now, Abivax Shares remain under pressure as investors weigh exceptional clinical efficacy against lingering safety concerns. The upcoming FDA submission and additional regulatory discussions will likely determine whether the recent selloff proves temporary or signals a longer period of uncertainty for the biotech company.

Disclaimer

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.